Sinobiopharma receives certificate for using Gabexate Mesylate as pharmaceutical raw material

Download PDF Copy

Oct 8 2009

Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma") (the "Company") is pleased to announce that the Company received a certificate for the use of Gabexate mesylate as a pharmaceutical raw material (Certificate #2009S01805) from the Chinese State Food and Drug Administration ("SFDA").

Gabexate Mesylate is a serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.

The Company is now awaiting GMP certification to manufacture Gabexate mesylate.

SOURCE Sinobiopharma, Inc.

Posted in: Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

New treatment approach developed to prevent lupus nephritis

New study reveals long road to seizure control for people with focal epilepsy

CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies

Edible microbeads trap fat to support weight loss

Gene editing restores hearing and balance in adult mice with DFNA41 deafness

WHO expands global network of trusted medical product regulators

Targeting gut signaling protein may protect against alcohol-related liver damage

University of Maine team develops sustainable method to cut drug production costs

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.